Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NiCord expanded umbilical cord blood transplantation in adolescents and adults with hematologic malignancies
NL-OMON43606Phase 2Active, not recruiting
- Sponsor
- Gamida Cell
- Start
- Mar 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omidubicel in hematopoietic malignancies, leukemia, myelodysplastic syndrome (MDS) and 1 more, sponsored by Gamida Cell. Primary endpoints: Incidence of NiCord-derived neutrophil engraftment and Incidence of secondary graft failure. Started Mar 2015; status: active, not recruiting.
02
Drugs
omidubicel
03
Conditions
hematopoietic malignanciesleukemiamyelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NL-OMON43606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43606.